
Novavax (NVAX) Stock Forecast & Price Target
Novavax (NVAX) Analyst Ratings
Bulls say
Novavax is a commercial-stage biotechnology company that has received FDA approval and EC Marketing Authorization for their COVID vaccine Nuvaxovid and has entered a commercialization partnership with Sanofi for this vaccine. Their product pipeline, particularly the in-house development of a live attenuated flu/COVID combo vaccine and their Matrix-M adjuvant technology, could drive long-term value for the company. The efficacy and tolerability data for Nuvaxovid compared to the currently licensed mRNA vaccines could also contribute to their success in capturing market share in the COVID vaccine market.
Bears say
Novavax is facing several challenges, including potential competition in the maternal vaccine market, limited evidence of efficacy for their COVID-19 vaccine compared to other platforms, and potential vaccine hesitancy among the general population. Despite the recent ACIP recommendation for pregnant individuals to receive COVID-19, flu, and Tdap vaccinations, Novavax may struggle to capture a significant market share due to the dominance of Sanofi in the flu market and the targeted demographic for the two vaccines already overlapping. However, with the potential development of a monoclonal antibody approach similar to Invivyd's, Novavax may still have the opportunity to compete in the evolving COVID protection landscape. It will be important to closely monitor the uptake of COVID-19 vaccines and any potential developments in alternative prophylaxis approaches.
This aggregate rating is based on analysts' research of Novavax and is not a guaranteed prediction by Public.com or investment advice.
Novavax (NVAX) Analyst Forecast & Price Prediction
Start investing in Novavax (NVAX)
Order type
Buy in
Order amount
Est. shares
0 shares